Supported by product characterization and prior knowledge about the molecule class, quality attributes with potential impact on efficacy and/or safety were identified and classified as CQAs.Directly linked to the analysis of the CQAs is their relationship to the tafasitamab process and the CPPs, the assessment of the capability of the process to control them, and the appropriate control strategy for commercial manufacturing based on all the collective product and process knowledge.Process parameters have been evaluated through a risk assessment and extensive process characterization studies with additional focus on the identification of CPPs that may impact CQAs.